139 related articles for article (PubMed ID: 18559769)
1. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Hong DS; Reddy SB; Prieto VG; Wright JJ; Tannir NM; Cohen PR; Diwan AH; Evans HL; Kurzrock R
Arch Dermatol; 2008 Jun; 144(6):779-82. PubMed ID: 18559769
[TBL] [Abstract][Full Text] [Related]
2. [Squamous cell carcinoma in a patient receiving sorafenib].
Adnot-Desanlis L; Bernard P; Reguiaï Z
Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
[TBL] [Abstract][Full Text] [Related]
3. The histologic spectrum of epithelial neoplasms induced by sorafenib.
Kwon EJ; Kish LS; Jaworsky C
J Am Acad Dermatol; 2009 Sep; 61(3):522-7. PubMed ID: 19700018
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib-induced eruptive melanocytic lesions.
Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
[No Abstract] [Full Text] [Related]
5. Invasive squamous cell carcinoma and sorafenib in a black patient.
Donaldson MR; Stetson CL; Smith JL
Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
[No Abstract] [Full Text] [Related]
6. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
Degen A; Satzger I; Voelker B; Kapp A; Hauschild A; Gutzmer R
Dermatology; 2010; 221(3):193-6. PubMed ID: 20720388
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Dubauskas Z; Kunishige J; Prieto VG; Jonasch E; Hwu P; Tannir NM
Clin Genitourin Cancer; 2009 Jan; 7(1):20-3. PubMed ID: 19213663
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
9. Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Lynch MC; Straub R; Adams DR
J Drugs Dermatol; 2011 Mar; 10(3):308-10. PubMed ID: 21369650
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
11. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Smith KJ; Haley H; Hamza S; Skelton HG
Dermatol Surg; 2009 Nov; 35(11):1766-70. PubMed ID: 19660024
[TBL] [Abstract][Full Text] [Related]
12. [Sorafenib-induced multiple eruptive keratoacanthomas].
Jantzem H; Dupre-Goetghebeur D; Spindler P; Merrer J
Ann Dermatol Venereol; 2009 Dec; 136(12):894-7. PubMed ID: 20004316
[TBL] [Abstract][Full Text] [Related]
13. Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
Galán Brotons A; Borrás-Blasco J; Rosique-Robles JD; Vicent Verge JM; Casterá ME
Clin Transl Oncol; 2008 Dec; 10(12):844-6. PubMed ID: 19068457
[TBL] [Abstract][Full Text] [Related]
14. [Sorafenib(Nexavar)].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
17. Acute pancreatitis associated with sorafenib.
Li M; Srinivas S
South Med J; 2007 Sep; 100(9):909-11. PubMed ID: 17902294
[TBL] [Abstract][Full Text] [Related]
18. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Breaker K; Naam M; La Rosa FG; Flaig IP; Flaig TW
Dermatol Surg; 2013 Jul; 39(7):981-7. PubMed ID: 23464361
[TBL] [Abstract][Full Text] [Related]
19. Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
Raymond AK; Puri PK; Selim MA; Tyler DS; Nelson KC
Arch Dermatol; 2010 Dec; 146(12):1438-9. PubMed ID: 21173337
[No Abstract] [Full Text] [Related]
20. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Shaheen PE; Rini BI; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]